Roham Zamanian, MD
Enriched profileJames and Yvonne Wood Professor of Pulmonary Vascular Medicine · Stanford University School of Medicine
Roham Zamanian is James and Yvonne Wood Professor of Pulmonary Vascular Medicine at Stanford University School of Medicine. OpenAlex indexes 286 publications with 10,119 citations (h-index 56); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Roham Zamanian, MD, is James and Yvonne Wood Professor of Pulmonary Vascular Medicine at Stanford University School of Medicine, Department of Medicine, Division of Pulmonary, Allergy & Critical Care Medicine. The public record shows 286 publications with 10,119 citations (h-index 56), centered on Pulmonary Hypertension Research and Treatments, Cardiovascular Function and Risk Factors, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 7 companies, 2 NIH-funded awards (2017–2025).
- Most recent indexed publication: 2026 · American journal of respiratory and critical care medicine
- Top research focus: Pulmonary Hypertension Research and Treatments
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 130.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Sponsor: Novartis Pharmaceuticals
Industry payments
Updated 16 Oct 2026
7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202511 payments$21,225openpaymentsdata.cms.gov ↗
- United Therapeutics CorporationProgram year20258 payments$11,063openpaymentsdata.cms.gov ↗
- Actelion Pharmaceuticals US, Inc.Program year20246 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
52.2%Endothelin Receptor Antagonist42.6%Ambrisentan76%Letairis25%Part D<11 patientsLoop diuretic9.6%Furosemide100%Part D<11 patientsGenitourinary & hormones
47.8%Phosphodiesterase 5 Inhibitor47.8%Sildenafil Citrate80%Tadalafil20%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
2 NIH research awards on record, funded 2017–2025 per NIH RePORTER. The latest:
- 1/2 A Phase 2 Study of Elafin (Tiprelestat) for the Treatment of Pulmonary Arterial Hypertension (PAH)
Stanford University
FY2025$1,998,124UG3HL180990 - Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension
University of Pennsylvania
FY2025$714,004R01HL159886 - Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension
University of Pennsylvania
FY2024$683,215R01HL159886
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Identification of Pulmonary Arterial Hypertension Patients with Venous or Capillary Involvement.
American journal of respiratory and critical care medicine
Article2026 - Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension.
American journal of respiratory and critical care medicine
Article2026 - Incident Atrial Fibrillation and Flutter in Patients With Pulmonary Arterial Hypertension: Influence of Right Ventricular Dilatation and Reduced Right Atrial Function.
Journal of the American Heart Association
Article2026 - Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study.
Advances in therapy
Clinical Trial2025 - Medication Nonadherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR).
Annals of the American Thoracic Society
Article2025
Most-cited works
by citation count (OpenAlex)Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/roham-zamanian-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/roham-zamanian-3bbbb110
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Roham-Zamanian
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
phaware.global/whoweare
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phaware.global ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- Internal Medicine Residency
UC Irvine Medical Center (2002); Pulmonary & Critical Care Fellowship, UC Irvine Medical Center (2003) and Stanford University (2005); Super-Fellowship in Pulmonary Vascular Disease …
2005verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stanfordhealthcare.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- Director
Adult Pulmonary Hypertension Service, Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University
2007verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stanfordhealthcare.org ↗
- Co-editor
"Pulmonary Hypertension: Basic Science to Clinical Medicine" (Springer), with Bradley A. Maron and Aaron B. Waxman
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →amazon.com ↗ - Editorial board member
Pulmonary Circulation (SAGE journal)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →journals.sagepub.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stanfordhealthcare.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phaware.global ↗
- Member
Stanford Cardiovascular Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗ - Member
Wu Tsai Human Performance Alliance, Stanford University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Media & interviews
press, podcasts and appearances- Stanford Medicine News feature: "The two years of living dangerously: One doctor's journey to the United States" (2010)
profile/interview on his emigration story
2010verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗ - "I'm Aware That I'm Rare: the phaware podcast"
Episode 345 (guest, on the 20th Annual Race Against PH at Stanford)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phaware.medium.com ↗ - "I'm Aware That I'm Rare: the phaware podcast"
Episode 527, MD, FCCP (guest, discusses "disease modification" concept in PH treatment)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phaware.medium.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Heidenreich, MD
Stanford University School of Medicine
Alan Schatzberg, MD
Stanford University School of Medicine
Euan Ashley, MD
Stanford University School of Medicine
Mark Pegram, MD
Stanford University School of Medicine
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Marshall University
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital